195 related articles for article (PubMed ID: 26332546)
1. Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia.
Baerlocher GM; Oppliger Leibundgut E; Ottmann OG; Spitzer G; Odenike O; McDevitt MA; Röth A; Daskalakis M; Burington B; Stuart M; Snyder DS
N Engl J Med; 2015 Sep; 373(10):920-8. PubMed ID: 26332546
[TBL] [Abstract][Full Text] [Related]
2. A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis.
Tefferi A; Lasho TL; Begna KH; Patnaik MM; Zblewski DL; Finke CM; Laborde RR; Wassie E; Schimek L; Hanson CA; Gangat N; Wang X; Pardanani A
N Engl J Med; 2015 Sep; 373(10):908-19. PubMed ID: 26332545
[TBL] [Abstract][Full Text] [Related]
3. Dynamics of mutations in patients with essential thrombocythemia treated with imetelstat.
Oppliger Leibundgut E; Haubitz M; Burington B; Ottmann OG; Spitzer G; Odenike O; McDevitt MA; Röth A; Snyder DS; Baerlocher GM
Haematologica; 2021 Sep; 106(9):2397-2404. PubMed ID: 32732354
[TBL] [Abstract][Full Text] [Related]
4. Telomerase Inhibitor Imetelstat in Essential Thrombocythemia and Myelofibrosis.
Baerlocher GM; Burington B; Snyder DS
N Engl J Med; 2015 Dec; 373(26):2580. PubMed ID: 26699176
[No Abstract] [Full Text] [Related]
5. Telomerase Inhibitor Imetelstat in Essential Thrombocythemia and Myelofibrosis.
Tefferi A
N Engl J Med; 2015 Dec; 373(26):2580-1. PubMed ID: 26709404
[No Abstract] [Full Text] [Related]
6. Telomerase Inhibitor Imetelstat in Essential Thrombocythemia and Myelofibrosis.
Bjørn ME; Nielsen CH; Hasselbalch HC
N Engl J Med; 2015 Dec; 373(26):2579-80. PubMed ID: 26699178
[No Abstract] [Full Text] [Related]
7. Telomerase Inhibitor Imetelstat in Essential Thrombocythemia and Myelofibrosis.
El Fassi D
N Engl J Med; 2015 Dec; 373(26):2579. PubMed ID: 26699177
[No Abstract] [Full Text] [Related]
8. A phase I trial of imetelstat in children with refractory or recurrent solid tumors: a Children's Oncology Group Phase I Consortium Study (ADVL1112).
Thompson PA; Drissi R; Muscal JA; Panditharatna E; Fouladi M; Ingle AM; Ahern CH; Reid JM; Lin T; Weigel BJ; Blaney SM
Clin Cancer Res; 2013 Dec; 19(23):6578-84. PubMed ID: 24097866
[TBL] [Abstract][Full Text] [Related]
9. Somatic mutations of calreticulin in myeloproliferative neoplasms.
Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
[TBL] [Abstract][Full Text] [Related]
10. Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia.
Antonioli E; Guglielmelli P; Poli G; Bogani C; Pancrazzi A; Longo G; Ponziani V; Tozzi L; Pieri L; Santini V; Bosi A; Vannucchi AM;
Haematologica; 2008 Jan; 93(1):41-8. PubMed ID: 18166784
[TBL] [Abstract][Full Text] [Related]
11. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
[TBL] [Abstract][Full Text] [Related]
12. A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study.
Salloum R; Hummel TR; Kumar SS; Dorris K; Li S; Lin T; Daryani VM; Stewart CF; Miles L; Poussaint TY; Stevenson C; Goldman S; Dhall G; Packer R; Fisher P; Pollack IF; Fouladi M; Boyett J; Drissi R
J Neurooncol; 2016 Sep; 129(3):443-451. PubMed ID: 27350411
[TBL] [Abstract][Full Text] [Related]
13. Telomerase antagonist imetelstat inhibits esophageal cancer cell growth and increases radiation-induced DNA breaks.
Wu X; Smavadati S; Nordfjäll K; Karlsson K; Qvarnström F; Simonsson M; Bergqvist M; Gryaznov S; Ekman S; Paulsson-Karlsson Y
Biochim Biophys Acta; 2012 Dec; 1823(12):2130-5. PubMed ID: 22906540
[TBL] [Abstract][Full Text] [Related]
14. Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with JAK2-V617F mutation.
Hexner E; Roboz G; Hoffman R; Luger S; Mascarenhas J; Carroll M; Clementi R; Bensen-Kennedy D; Moliterno A
Br J Haematol; 2014 Jan; 164(1):83-93. PubMed ID: 24903629
[TBL] [Abstract][Full Text] [Related]
15. Imetelstat, a telomerase inhibitor, differentially affects normal and malignant megakaryopoiesis.
Mosoyan G; Kraus T; Ye F; Eng K; Crispino JD; Hoffman R; Iancu-Rubin C
Leukemia; 2017 Nov; 31(11):2458-2467. PubMed ID: 28270692
[TBL] [Abstract][Full Text] [Related]
16. Direct evidence for normalization of platelet function resulting from platelet count reduction in essential thrombocythemia.
Tsantes AE; Nikolopoulos GK; Tsirigotis P; Zoi K; Zomas A; Kapsimali V; Kopterides P; Chondropoulos S; Dervenoulas J; Mantzios G
Blood Coagul Fibrinolysis; 2011 Sep; 22(6):457-62. PubMed ID: 21836466
[TBL] [Abstract][Full Text] [Related]
17. Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history.
Gangat N; Wassie EA; Lasho TL; Finke C; Ketterling RP; Hanson CA; Pardanani A; Wolanskyj AP; Maffioli M; Casalone R; Passamonti F; Tefferi A
Eur J Haematol; 2015 Jan; 94(1):31-6. PubMed ID: 24889737
[TBL] [Abstract][Full Text] [Related]
18. Treating Myeloproliferation--On Target or Off?
Armanios M; Greider CW
N Engl J Med; 2015 Sep; 373(10):965-6. PubMed ID: 26332552
[No Abstract] [Full Text] [Related]
19. Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.
Hussein K; Brakensiek K; Buesche G; Buhr T; Wiese B; Kreipe H; Bock O
Ann Hematol; 2007 Apr; 86(4):245-53. PubMed ID: 17262192
[TBL] [Abstract][Full Text] [Related]
20. Telomerase antagonist imetelstat increases radiation sensitivity in esophageal squamous cell carcinoma.
Wu X; Zhang J; Yang S; Kuang Z; Tan G; Yang G; Wei Q; Guo Z
Oncotarget; 2017 Feb; 8(8):13600-13619. PubMed ID: 28099140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
